Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nisha Mohindra, M.D.
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
- Iu Health Central Indiana Cancer Center
Indianapolis, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Jun 2015
- Primary completion
- 14 Apr 2022
- Completion
- 14 Apr 2022
- Last update posted
- 23 May 2023
- Registered enrollment
- 46
- Registry id
- NCT02382406
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.